Effect of Immune-Modulatory Interventions on Asymptomatic Cytomegalovirus Shedding during Suppressive Antiretroviral Therapy.
Elizabeth HastieCarlee MoserXin SunJeffrey LennoxPriscilla Y HsueRonald J BoschSteven DeeksMilenka V MenesesMichael M LedermanPeter W HuntTimothy J HenrichVincent C MarconiSara GianellaPublished in: The Journal of infectious diseases (2023)
Long-term consequences of HIV are likely the result of persistent inflammation and immune dysfunction of which CMV is a known contributor. We leveraged two ACTG clinical trials exploring effects of immune modulators (ruxolitinib and sirolimus) on inflammation in people with HIV on ART to determine if these interventions affected CMV shedding at various mucosal sites. Analyzing 635 mucosal samples collected, we found no significant difference in CMV levels across study arms or time points. Men had more CMV shedding than women. We did confirm an association between higher CMV DNA and immune markers associated with HIV persistence and HIV-associated mortality.
Keyphrases
- antiretroviral therapy
- hiv infected
- hiv positive
- human immunodeficiency virus
- hiv aids
- hiv infected patients
- hiv testing
- hepatitis c virus
- men who have sex with men
- oxidative stress
- clinical trial
- physical activity
- south africa
- small molecule
- epstein barr virus
- coronary artery disease
- randomized controlled trial
- polycystic ovary syndrome
- circulating tumor
- adipose tissue
- metabolic syndrome